Encorafenib and Binimetinib: First Global Approvals

@article{Shirley2018EncorafenibAB,
  title={Encorafenib and Binimetinib: First Global Approvals},
  author={M. Shirley},
  journal={Drugs},
  year={2018},
  volume={78},
  pages={1277-1284}
}
Encorafenib (Braftovi™), a BRAF inhibitor, and binimetinib (Mektovi®), a MEK inhibitor, are two orally bioavailable drugs developed by Array BioPharma. In June 2018 they each received their first global approval, in the USA, for use in combination, for patients with unresectable or metastatic melanoma with a BRAFV600E or -V600K mutation as detected by an FDA-approved test. Registration applications for encorafenib and binimetinib for use in combination in the treatment of BRAF-mutation-positive… Expand

Topics from this paper

A patent review of BRAF inhibitors: 2013-2018
Current Advances in the Treatment of BRAF-Mutant Melanoma
The Role of Immune Checkpoint Blockade in Uveal Melanoma
Many ways to resistance: How melanoma cells evade targeted therapies.
...
1
2
3
...

References

SHOWING 1-10 OF 13 REFERENCES
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
BRAF inhibitors in cancer therapy.
Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms.
binimetinib) tablets: US prescribing information
  • 2018. https ://www.acces sdata .fda.gov/drugs atfda _docs/label /2018/21049 8lbl.pdf. Accessed 20 Jul
  • 2018
encorafenib) capsules: US prescribing information
  • 2018. https ://www.acces sdata .fda.gov/drugs atfda _docs/ label /2018/21049 6lbl.pdf. Accessed 20 Jul
  • 2018
approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations
  • 2018. https ://www.fda.gov/drugs /infor matio nondr ugs/appro veddr ugs/ucm61 1981.htm. Accessed 20 Jul
  • 2018
designations and approvals
  • 2013. https ://www.acces sdata .fda.gov/scrip ts/opdli sting /oopd/detai ledIn dex. cfm?cfgri dkey=41161 3. Accessed 20 Jul
  • 2018
...
1
2
...